Departments of Pharmacology.
Departments of Psychiatry, The Addiction Research, Treatment and Training Center of Excellence, University of Texas Health Science Center at San Antonio, Texas, USA.
Behav Pharmacol. 2021 Jun 1;32(4):278-285. doi: 10.1097/FBP.0000000000000610.
Intravenous drug self-administration remains the 'gold standard' for assessing abuse liability. Failure of a drug to maintain self-administration might indicate the absence of positive reinforcing effects but might also indicate the presence of aversive effects. Sensitivity to aversive and punishing effects of drugs (as well as nondrug stimuli) might collectively determine the likelihood of use, abuse and relapse. Using a choice procedure, this study compared the effects of remifentanil (mu opioid receptor agonist; 0.001-0.01 mg/kg/infusion) and histamine (H1-4 receptor agonist; 0.32-3.2 mg/kg/infusion), alone and in mixtures, to test the hypothesis that remifentanil/histamine mixtures are less reinforcing compared with remifentanil alone and less punishing compared with histamine alone. Male Sprague-Dawley rats (n = 10) chose between an intravenous infusion + a pellet and a pellet alone. Rats were indifferent to saline, chose remifentanil + a pellet over a pellet alone, and chose a pellet alone over histamine + a pellet. The effects of remifentanil/histamine mixtures generally were different from the constituent doses of histamine alone but not from remifentanil alone. A mixture containing 3.2 mg/kg/infusion histamine and either 0.001 or 0.0032 mg/kg/infusion remifentanil was not different from saline but was different from the effects of the constituent dose, insofar as choice increased compared with 3.2 mg/kg/infusion histamine alone and decreased compared with 0.001 or 0.0032 mg/kg/infusion remifentanil alone. Reinforcing doses of remifentanil combined with punishing doses of histamine can yield mixtures that are neither preferred nor avoided, offering 'proof-of-principle' for using drug mixtures to avoid adverse effects of opioid receptor agonists.
静脉药物自我给药仍然是评估滥用倾向的“金标准”。药物不能维持自我给药可能表明缺乏正强化作用,但也可能表明存在厌恶作用。对药物(以及非药物刺激)的厌恶和惩罚作用的敏感性可能共同决定使用、滥用和复发的可能性。本研究使用选择程序比较了瑞芬太尼(μ 阿片受体激动剂;0.001-0.01 mg/kg/输注)和组胺(H1-4 受体激动剂;0.32-3.2 mg/kg/输注)单独和混合物的作用,以检验瑞芬太尼/组胺混合物的假设比单独的瑞芬太尼的强化作用更小,比单独的组胺的惩罚作用更小。雄性 Sprague-Dawley 大鼠(n=10)在静脉输注+药丸和单独药丸之间进行选择。大鼠对生理盐水无反应,选择瑞芬太尼+药丸而不是单独的药丸,并且选择单独的药丸而不是组胺+药丸。瑞芬太尼/组胺混合物的作用通常与单独使用组胺的组成剂量不同,但与单独使用瑞芬太尼的作用不同。含有 3.2 mg/kg/输注组胺和 0.001 或 0.0032 mg/kg/输注瑞芬太尼的混合物与生理盐水没有区别,但与组成剂量的作用不同,因为与单独使用 3.2 mg/kg/输注组胺相比,选择增加,与单独使用 0.001 或 0.0032 mg/kg/输注瑞芬太尼相比,选择减少。瑞芬太尼的强化剂量与组胺的惩罚剂量相结合可以产生既不被偏好也不被回避的混合物,为使用药物混合物避免阿片受体激动剂的不良反应提供了“原理证明”。